Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one allele: 144-week interim results from a 192-week open-label extension study.
Elizabeth Tullis, Cori L Daines, Stefano Costa, Rachel W Linnemann, Marcus A Mall, Edward F McKone, Deepika Polineni, Bradley S Quon, Felix C Ringshausen, Steven M Rowe, Hiran Selvadurai, Jennifer L Taylor-Cousar, Nicholas J Withers, Neil Ahluwalia, Samuel M Moskowitz, Valentin Prieto-Centurion, Yaoyuan Vincent Tan, Simon Tian, Tanya Weinstock, Fengjuan Xuan, Yaohua Zhang, Bonnie Ramsey, Matthias Griese
The European respiratory journal 2024;62(6):2202029